Hematology integrated 19 subjects of neet pg and teach me from scratch

Reading File

Asking for Preferences

Finding Sources

Searching Images

hematopoiesis blood cell development diagram

This medical illustration presents a comparative timeline of the embryonic origin and progression of the hematopoietic system in three developmental models: zebrafish (A), chicken (B), and Xenopus (C). The diagram categorizes hematopoietic waves into primitive, transient, and definitive stages. Panel A (Zebrafish) tracks development from 6 hours post-fertilization (hpf) to 6 days, highlighting the rostral blood islands (RBI) and posterior-lateral mesoderm (PLM). Key structures shown include the intermediate cell mass (ICM), the caudal hematopoietic tissue (CHT) within the tail vascular plexus (comprising the dorsal aorta, caudal artery, and caudal vein), and the eventual colonization of the thymus and kidney marrow. Panel B (Chicken) illustrates the progression from day 1 to day 21, detailing primitive hematopoiesis in the yolk sac (YS) blood islands, followed by the aorta-gonad-mesonephros (AGM) region. It shows the later emergence of the spleen, bursa, thymus, and bone marrow (BM) as definitive sites. Panel C (Xenopus) depicts stages from the 32-cell stage through metamorphosis, focusing on the ventral blood island (VBI), dorsal aorta (DA), and the liver as a primary definitive site. The diagrams use cross-sectional views to relate hematopoietic sites to anatomical landmarks like the neural plate, notochord, and somites.

A three-part educational diagram illustrating hematopoiesis, neutrophil differentiation, and bone marrow egress. Section (a) shows the hematopoietic lineage from multipotent hematopoietic stem cells (HSCs) to mature myeloid cells. It depicts the common myeloid progenitor (CMP) giving rise to the granulocyte-macrophage progenitor (GMP), which differentiates into neutrophils, basophils, and eosinophils under the influence of growth factors like G-CSF, IL-5, and GM-CSF. Macrophage development is shown via a myeloid progenitor (MP) and monocyte intermediate, regulated by M-CSF. Section (b) details neutrophil maturation in the bone marrow, categorized into stem cell, mitotic, and post-mitotic pools. It visualizes morphological changes from the myeloblast through the promyelocyte, myelocyte (kidney-shaped nucleus), and metamyelocyte (horseshoe-shaped nucleus) to the segmented mature neutrophil. Section (c) illustrates bone marrow egress, where stromal cell-derived CXCL12 binding to CXCR4 promotes neutrophil retention, while CXCL1 and CXCL2 binding to CXCR2 facilitates egress into the peripheral blood.

This pathophysiology diagram illustrates the revised hierarchical model of human hematopoiesis. At the apex, long-term hematopoietic stem cells (LT-HSC) exhibit self-renewal and differentiate into multipotent progenitors (MPP). The lineage then diverges into two primary branches: the common myeloid progenitor (CMP) and the common lymphoid progenitor (CLP). The myeloid branch further splits into megakaryocyte-erythrocyte progenitors (MEP), yielding erythrocytes and platelets, and granulocyte-monocyte progenitors (GMP), yielding granulocytes and monocytes. The lymphoid branch differentiates through intermediate progenitors (ETP and B/NK) to produce T-cells, B-cells, and NK-cells, with dendritic cells originating from both GMP and CLP pathways. Notably, the diagram features a 'MEP Bypass' route, showing a direct differentiation pathway from LT-HSC to MEP, bypassing the standard MPP and CMP stages. Progenitor cells are represented by color-coded circular icons, while mature blood cells are depicted with characteristic morphological features. This visual resource is intended for medical education regarding stem cell biology and hematological development.

Reading File

Loading Image

Finding Sources

Searching Images

anemia classification MCV microcytic macrocytic normocytic

This composite educational graphic presents hematological longitudinal data and diagnostic brain imaging for two pediatric patients. Panels A and B contain line graphs tracking Blood-Hemoglobin (B-Hb), Mean Corpuscular Volume (B-MCV), and reticulocyte counts against age in months, highlighting periods of macrocytic anemia and hospitalization. Panels C-F show axial and sagittal CT scans of the brain from an 8-month-old (Patient II:7), demonstrating diffuse cerebral edema characterized by reduced attenuation of the supratentorial gray matter, compression of the lateral ventricles, and flattening of the extracerebral CSF spaces. Arrows indicate a loss of gray-white matter differentiation and signs of herniation through the tentorium and foramen magnum. Panels G-I display T2-weighted MRI scans in axial, coronal, and sagittal planes for Patient II:8 at 8 months of age. White arrows highlight symmetrically increased T2 signal intensity in the thalamus, globus pallidus, and patchy areas within the cortical and subcortical regions of the fronto-parietal and occipital lobes, indicative of metabolic or inflammatory brain injury.

Educational figure illustrating hematological abnormalities in a murine model of Prkab1 deficiency, serving as a surrogate for studying human hemolytic anemia and microcytosis. Panels A-F present dot plots of hematological indices for wild-type (Prkab1+/+) and deficient (Prkab1tm1b/tm1b) mice, showing significant reductions in hemoglobin (A), hematocrit (B), and mean corpuscular volume (E), with a concomitant increase in red blood cell distribution width (F), indicating microcytic anemia with anisocytosis. Panel G contains high-resolution Scanning Electron Microscopy (SEM) images comparing erythrocyte morphology; wild-type cells show standard biconcave discocyte morphology, whereas Prkab1-deficient cells exhibit poikilocytosis with numerous abnormal forms, including acanthocytes, schistocytes, and echinocytes with irregular surface protrusions. Panel H displays an osmotic resistance curve, where Prkab1-deficient erythrocytes demonstrate a left-ward shift, signifying increased osmotic resistance (delayed hemolysis) compared to wild-type controls. The inset confirms a lower NaCl percentage required for 50% hemolysis in deficient cells, indicating altered membrane stability.

Reading File

Finding Sources

Here is your complete NEET PG Hematology - From Scratch integrated teaching session. This covers all 19 subjects integrated (Physiology, Biochemistry, Pathology, Medicine, Pharmacology, Forensics, Pediatrics, Obs/Gynae, Microbiology, Surgery, etc.) with high-yield MCQ focus.

🩸 HEMATOLOGY FOR NEET PG - COMPLETE FROM SCRATCH

MODULE 1: HEMATOPOIESIS (Foundation)

1.1 Sites of Hematopoiesis - THE MOST MCQ-TESTED TOPIC

Age	Primary Site	Mnemonic
0-2 weeks embryo	Yolk sac	Young Yolk
2nd month	AGM region (Aorta-Gonad-Mesonephros)
3rd-7th month fetus	Liver (chief site) + Spleen	Liver Loves 3rd month
4th month onwards	Bone marrow (starts)
Birth onwards	Bone marrow only
After puberty	Axial skeleton only (vertebrae, sternum, ribs, skull, pelvis)

MCQ ALERT: In adults, only ~50% of marrow space is hematopoietically active (red marrow). Yellow marrow = fat, inactive.

Pathology integration: When bone marrow fails (aplastic anemia, leukemia), the body reverts to liver and spleen = Extramedullary hematopoiesis (EMH). This causes hepatosplenomegaly.

1.2 Hematopoietic Cell Hierarchy

Here is the actual diagram from Robbins Pathology showing the full cell lineage:

Hematopoiesis - Differentiation of blood cells (Robbins)

Key hierarchy (NEET-critical):

HSC (Hematopoietic Stem Cell)
  ├── Common Lymphoid Progenitor (CLP)
  │     ├── Pro-B → Pre-B → B cell
  │     ├── Pro-T → Pre-T → T cell
  │     └── Pro-NK → NK cell
  └── Common Myeloid Progenitor (CMP)
        ├── CFU-GEMM (Mix)
        │     ├── CFU-E → Erythroblast → Erythrocyte
        │     ├── CFU-Meg → Megakaryoblast → Platelets
        │     ├── CFU-G → Myeloblast → Neutrophil
        │     ├── CFU-M → Monoblast → Monocyte
        │     ├── CFU-eo → Eosinophiloblast → Eosinophil
        │     └── CFU-b → Basophiloblast → Basophil

MCQ: HSC markers = CD34+, CD117 (c-KIT)+, Lin- (lineage negative). Used for stem cell transplantation identification.

Pharma integration: Growth factors used clinically:

EPO (Erythropoietin) - stimulates CFU-E → used in renal anemia (Darbepoetin = long-acting EPO)
G-CSF (Filgrastim) - stimulates neutrophil production → used post-chemotherapy
GM-CSF (Sargramostim) - stimulates myeloid line broadly
TPO (Thrombopoietin/Eltrombopag) - stimulates megakaryocytes → used in ITP

MODULE 2: NORMAL BLOOD VALUES (Physiology + Biochem)

2.1 Critical Normal Values - MEMORIZE THESE

Parameter	Normal Value	MCQ Trick
Hemoglobin Men	13.5-17.5 g/dL	<13 = anemia in men
Hemoglobin Women	12-16 g/dL	<12 = anemia in women
Hb in pregnancy	<11 g/dL = anemia (WHO)	Lower due to dilution
Hb Newborn	18-22 g/dL (highest!)	Due to HbF
MCV	80-100 fL	Memory: 80-100 = normal
MCH	27-32 pg
MCHC	32-36 g/dL	Most sensitive index of IDA
RBC count	M: 4.5-5.5 million; F: 3.8-4.8 million
Reticulocytes	0.5-2.5%	Elevated = active hemolysis/blood loss
WBC	4000-11000/mm³
Platelets	1.5-4 lakh/mm³ (150,000-400,000)
ESR (Westergren)	M: <15 mm/hr; F: <20 mm/hr
Hematocrit (PCV)	M: 40-52%; F: 37-47%	PCV = Hb × 3 (approx)

MCQ: Wintrobe's indices (MCV, MCH, MCHC) are calculated from Hb, RBC count, and PCV. These are the indices used to classify anemia.

MODULE 3: HEMOGLOBIN (Biochemistry Integration)

3.1 Hemoglobin Structure

Structure: Tetramer - 2 alpha + 2 non-alpha chains + 4 heme groups
Each heme = Protoporphyrin IX + Fe²⁺
Fe²⁺ (ferrous) carries O₂; Fe³⁺ (ferric) = methemoglobin (can't carry O₂)

3.2 Types of Normal Hemoglobin

Type	Chains	% in Adult	Key Point
HbA	α₂β₂	96-98%	Main adult Hb
HbA₂	α₂δ₂	2-3%	Increased in β-thalassemia trait
HbF	α₂γ₂	<1% adult; 70% at birth	Higher O₂ affinity than HbA
HbGower	ζ₂ε₂	Embryonic only	First embryonic Hb

MCQ: HbF has higher O₂ affinity than HbA because 2,3-DPG binds less to γ chains. This is why HbF shifts the ODC to the LEFT.

3.3 Hemoglobin Switching

Embryo:  HbGower → HbPortland
Fetus:   HbF (peaks at 8-10 weeks, declines near birth)
Adult:   HbA takes over by 6 months of age

MCQ: At birth, 70% is HbF. By 6 months, HbA predominates. This is why sickle cell disease and β-thal manifest after 6 months of age (when HbF declines).

3.4 Oxygen Dissociation Curve (ODC) - HIGH YIELD

RIGHT shift (↓ O₂ affinity, ↑ O₂ delivery to tissues):

↑ CO₂, ↑ Temperature, ↑ 2,3-DPG, ↑ H⁺ (↓ pH) = Bohr effect
Sickle cell disease (HbS polymerizes when deoxygenated)

LEFT shift (↑ O₂ affinity, ↓ O₂ release):

CO poisoning (HbCO), Methemoglobin, HbF, Alkalosis, ↓ 2,3-DPG

MCQ: Stored blood has ↓ 2,3-DPG → LEFT shift → poor O₂ delivery. Packed cells transfused for major surgery need to be fresh for this reason.

MODULE 4: CLASSIFICATION OF ANEMIA - THE MASTER FRAMEWORK

4.1 Two-Way Classification (NEET standard)

BY MCV (Wintrobe's morphologic classification):

Type	MCV	Causes	Mnemonic
Microcytic	<80 fL	Iron deficiency, Thalassemia, ACD, Sideroblastic	TAILS (Thalassemia, Anemia of chronic disease, Iron deficiency, Lead poisoning, Sideroblastic)
Normocytic	80-100 fL	Aplastic anemia, Hemolysis, Renal failure, Acute blood loss	HARM (Hemolysis, Aplastic, Renal, Marrow infiltration)
Macrocytic	>100 fL	B12/Folate deficiency, Liver disease, Hypothyroidism, Alcohol, Drugs	Oval macrocytes = megaloblastic; Round macrocytes = non-megaloblastic

BY MECHANISM (Pathology-based):

Decreased production (hypoproliferative - low reticulocytes)
- Iron/B12/Folate deficiency
- Aplastic anemia
- Anemia of chronic disease
- Bone marrow infiltration (myelophthisis)
Increased destruction (Hemolysis) (high reticulocytes)
- Intravascular: G6PD, PNH, mechanical valves
- Extravascular: Spherocytosis, Sickle cell, Thalassemia
Blood loss (high reticulocytes if chronic, normal if acute)

MCQ KEY: The reticulocyte count is the single most important test to distinguish production problem (low retics) from destruction/loss (high retics).

MODULE 5: IRON DEFICIENCY ANEMIA (IDA) - Most Tested

5.1 Epidemiology

Most common nutritional deficiency worldwide (Medicine, Pathology)
Most common cause of anemia globally
Affects ~10% in high-resource countries, 25-50% in low-resource countries (Robbins)

5.2 Iron Metabolism (Biochemistry Integration)

Total body iron: 2.5 g (women) / 3.5 g (men)

80% in Hb, myoglobin, iron enzymes (cytochromes, catalase)
15-20% in storage form (ferritin + hemosiderin) in liver, spleen, bone marrow macrophages

Iron absorption:

Duodenum (primary site of absorption)
Fe³⁺ reduced to Fe²⁺ by duodenal cytochrome B (Dcytb/CYBRD1)
Fe²⁺ enters enterocyte via DMT-1 (Divalent Metal Transporter-1)
Exits basolateral side via Ferroportin
Re-oxidized by Hephaestin/Ceruloplasmin to Fe³⁺ → binds Transferrin in plasma

Hepcidin - The MASTER REGULATOR:

Made by liver
Degrades ferroportin → reduces iron absorption and macrophage iron release
↑ Hepcidin in inflammation (IL-6 induces it) → Anemia of Chronic Disease
↓ Hepcidin in iron deficiency and hemochromatosis

MCQ: Transferrin is normally 33% saturated. Serum iron averages 120 μg/dL (men), 100 μg/dL (women). Total iron-binding capacity (TIBC) = 300-350 μg/dL normally.

5.3 Stages of Iron Deficiency

Stage	Ferritin	Serum Iron	TIBC	Transferrin Sat	Hb	MCV
Stage 1: Storage depletion	↓	Normal	Normal	Normal	Normal	Normal
Stage 2: Iron-deficient erythropoiesis	↓	↓	↑	↓ (<20%)	Normal	Normal
Stage 3: IDA	↓	↓	↑	↓	↓	↓

MCQ: Ferritin is the earliest to fall. It is the best indicator of iron stores. But ferritin is also an acute phase reactant (rises in inflammation, liver disease, malignancy) - so can be falsely normal in IDA + infection.

5.4 IDA - Clinical Features (Medicine + Surgery Integration)

Symptoms of anemia: fatigue, pallor, dyspnea on exertion, palpitations

Iron-specific features:

Koilonychia (spoon-shaped nails) - Pathognomonic
Pica (craving for clay, ice = pagophagia, starch = amylophagia)
Angular cheilitis, glossitis (smooth tongue)
Plummer-Vinson (Paterson-Brown-Kelly) syndrome = IDA + dysphagia (postcricoid web) + atrophic glossitis → precancerous for hypopharyngeal carcinoma

5.5 Lab Findings in IDA

Lab Test	Finding in IDA
Hb	↓
MCV	↓ (<80 fL)
MCH	↓
MCHC	↓ (hypochromia) - most sensitive index
Serum ferritin	↓ (earliest, most sensitive)
Serum iron	↓
TIBC	↑ (body tries to absorb more)
Transferrin saturation	↓ (<15%)
Serum transferrin receptor (sTfR)	↑ (most specific for IDA, unaffected by inflammation)
Blood film	Microcytic, hypochromic, pencil cells, target cells
Reticulocytes	Normal/↓ (production problem)
Bone marrow	Absent iron stores (Prussian blue stain negative)

MCQ: In anemia of chronic disease (ACD): ferritin is NORMAL/↑, serum iron ↓, TIBC ↓ (unlike IDA where TIBC ↑). sTfR/log ferritin ratio differentiates IDA from ACD.

5.6 Treatment (Pharmacology Integration)

Oral iron: Ferrous sulfate 200 mg TDS (contains 60 mg elemental iron per tablet)
- Best absorbed on empty stomach (but GI side effects)
- Ascorbic acid (Vit C) increases absorption (reduces Fe³⁺ to Fe²⁺)
- Tetracyclines, antacids, PPIs, milk, phytates, tannins decrease absorption
- Duration: 3-6 months (continue 3 months after Hb normalizes to replenish stores)
- Reticulocyte count rises at 7-10 days (proof of treatment response)
- Hb rises by 1-2 g/dL per month
IV iron indications: Malabsorption, intolerance, inflammatory bowel disease, CKD on hemodialysis, need for rapid correction

MCQ: Cause of failure to respond to oral iron: 1) Non-compliance, 2) Ongoing blood loss, 3) Malabsorption, 4) Wrong diagnosis, 5) Concurrent folate/B12 deficiency

MODULE 6: MEGALOBLASTIC ANEMIA (Vitamin B12 and Folate)

6.1 Key Differences - B12 vs Folate

Feature	B12 Deficiency	Folate Deficiency
Neural tube defects	No	YES (periconceptional folate prevents NTDs)
Neurological features	YES - SACD (Subacute Combined Degeneration)	No neuro features
Serum methylmalonic acid	↑	Normal
Serum homocysteine	↑	↑
Serum folate	Normal or ↑	↓
RBC folate	↓ (trapped as methylTHF)	↓
Schilling test	Diagnoses B12 malabsorption	Not applicable

MCQ: The methyl-folate trap: B12 is needed to convert methylTHF → THF. Without B12, folate gets trapped as methylTHF → can't be used for DNA synthesis. This is why B12 deficiency causes megaloblastic anemia even with normal folate intake.

6.2 B12 (Cobalamin) - High-Yield Facts

Sources: Animal products only (meat, fish, eggs, dairy) - vegans at risk

Absorption pathway:

Food → released by acid + pepsin
Binds R-factor (haptocorrin) in stomach
In duodenum: pancreatic enzymes cleave R-factor → B12 binds Intrinsic Factor (IF) (made by gastric parietal cells)
IF-B12 complex absorbed at terminal ileum (via cubilin receptor)
Transported by Transcobalamin II (TC-II) in plasma

Causes of B12 deficiency:

Pernicious anemia (most common in developed world) = autoimmune gastritis → ↓ parietal cells → ↓ IF → ↓ B12 absorption. Anti-IF antibody = most specific (50% sensitive). Anti-parietal cell antibody = 90% sensitive but less specific
Strict veganism (no animal products)
Gastrectomy/gastric bypass
Terminal ileum resection (Crohn's disease)
Fish tapeworm (Diphyllobothrium latum) - competes for B12
Metformin (reduces B12 absorption - MCQ in pharmacology!)

MCQ: Body stores of B12 last 3-5 years (liver stores large amounts). Body stores of folate last only 3-4 months.

6.3 Neurological Features of B12 Deficiency - SACD

Subacute Combined Degeneration of spinal cord:

Affects posterior columns (vibration, proprioception lost first)
AND lateral corticospinal tracts (upper motor neuron signs)
Presents as: peripheral neuropathy + spastic paraparesis + ataxia

MCQ: SACD can occur WITHOUT macrocytic anemia (Hb can be normal). Giving folate to B12-deficient patient: corrects anemia BUT worsens neurological damage (the methyl-folate trap resolves, masking B12 deficiency). This is a classic NEET trap!

6.4 Blood Film in Megaloblastic Anemia

Oval macrocytes (not round)
Hypersegmented neutrophils (≥5 lobes in >5% neutrophils, or any cell with ≥6 lobes) - EARLIEST feature, appears before anemia
Pancytopenia in severe cases
Ineffective erythropoiesis (most RBC destroyed in marrow before reaching blood)
Bone marrow: giant metamyelocytes, megaloblasts

MODULE 7: HEMOLYTIC ANEMIAS

7.1 Classification of Hemolysis

By site:

Intravascular	Extravascular
Within blood vessels	In spleen, liver macrophages
Free Hb → hemoglobinuria (dark urine)	Bilirubin ↑ (indirect/unconjugated)
Haptoglobin ↓↓	Haptoglobin ↓ (less severe)
Hemosiderinuria	Splenomegaly
Schistocytes on film	Spherocytes on film
PNH, G6PD (triggered), TTP/HUS, mechanical	Hereditary spherocytosis, warm AIHA

Lab hallmarks of hemolysis (any type):

↑ LDH (released from RBCs)
↑ Indirect bilirubin → jaundice
↓ Haptoglobin (binds free Hb, then cleared by liver)
↑ Reticulocyte count (bone marrow response)
Blood film: polychromasia (blue-staining young RBCs)

7.2 Hereditary Spherocytosis (HS) - Pediatrics Integration

Most common inherited RBC membrane disorder (in Northern Europeans)
Autosomal dominant (75%) or recessive
Defect in spectrin (most common), ankyrin, band 3, or protein 4.2
These proteins anchor lipid bilayer to cytoskeleton → loss of membrane area → sphere shape

Diagnosis:

Osmotic fragility test (increased = spherocytes lyse in lower salt concentration) - traditional
EMA (Eosin-5-maleimide) binding test - newer, more specific (↓ binding in HS)
Coombs test negative (differentiates from AIHA which also has spherocytes)
Blood film: spherocytes (small, hyperchromic, no central pallor)

Complications:

Aplastic crisis - triggered by Parvovirus B19 (infects erythroblasts) - SUDDEN Hb drop
Megaloblastic crisis - folate depletion due to high RBC turnover
Hemolytic crisis - with infections
Pigment gallstones (bilirubin gallstones) from chronic hemolysis

Treatment: Splenectomy (reduces hemolysis; give vaccinations pre-splenectomy)

MCQ: Pre-splenectomy vaccines: Pneumococcal (PCV/PPSV23), Meningococcal, Haemophilus influenzae type b. Post-splenectomy: lifelong penicillin prophylaxis in children.

7.3 G6PD Deficiency - High Yield

X-linked recessive (males affected; females can be carriers)
Most common enzyme deficiency worldwide (protects against malaria)
Defect: G6PD enzyme (hexose monophosphate shunt) → ↓ NADPH → ↓ reduced glutathione → oxidative stress → Heinz body formation → RBC destruction

Triggers: Drugs (Primaquine, Dapsone, Nitrofurantoin, Sulfonamides), Fava beans, Infections, Naphthalene (mothballs)

Blood film: Bite cells (splenic macrophages bite out Heinz bodies) + Blister cells + Heinz bodies on supravital stain (crystal violet)

Diagnosis: G6PD enzyme assay (must do when patient is NOT in crisis - level falsely normal in crisis as deficient cells have already hemolyzed)

MCQ: G6PD deficiency is the most common cause of neonatal jaundice in many parts of India and Africa. Ascorbic acid in large doses can also trigger hemolysis.

7.4 Sickle Cell Disease (SCD) - Integrated High-Yield

Mutation: HbS = Glu → Val at position 6 of β-globin chain (GAG → GTG). Chromosome 11.

Pathophysiology: HbS polymerizes when deoxygenated → rigid sickle shape → vaso-occlusion + hemolysis

HbSS (sickle cell disease): ~100% HbS, severe HbSC: moderate disease HbS trait (HbAS): ~40% HbS, generally asymptomatic (protective against malaria)

Clinical features (Vaso-occlusive = Painful crisis):

Precipitated by: cold, infection, dehydration, hypoxia, stress
Dactylitis = hand-foot syndrome (first manifestation in infants, due to infarction of small bones)
Avascular necrosis of femoral head (most common AVN site)
Acute chest syndrome = commonest cause of death in SCD
Splenic sequestration crisis = rapid pooling of blood in spleen (toddlers, medical emergency)
Autosplenectomy by age 5 (repeated infarcts) → functional asplenia → susceptibility to encapsulated organisms (S. pneumoniae, H. influenzae, Salmonella typhi)
Salmonella = MC cause of osteomyelitis in SCD (not Staph aureus as in normal patients)
Priapism - painful, prolonged erection
Proliferative retinopathy, CVA (stroke) in children
Renal papillary necrosis → hematuria

Lab: Target cells, sickle cells, Howell-Jolly bodies (asplenia), elevated retics, ↑ bilirubin, ↑ LDH

Diagnosis:

Hb electrophoresis (gold standard)
Sickling test (sodium metabisulfite) - screening
Sickledex/Solubility test - can't differentiate trait from disease

Treatment:

Hydroxyurea - ↑ HbF production → dilutes HbS → fewer crises. Also ↑ NO production, reduces adhesion. (Pharma: myelosuppressive, need CBC monitoring)
Folic acid supplementation
Pneumococcal, meningococcal vaccines
Bone marrow transplant = only curative option
Voxelotor (new): prevents HbS polymerization
Crizanlizumab: anti-P-selectin monoclonal antibody, reduces vaso-occlusion
Painful crisis: IV fluids, analgesia (opioids), oxygen

MCQ: Prenatal diagnosis of SCD: chorionic villus sampling (CVS) at 10-12 weeks or amniocentesis at 15-20 weeks using PCR/DNA analysis.

MODULE 8: THALASSEMIA - Complete Coverage

8.1 α-Thalassemia

α-globin genes on chromosome 16 (4 copies: αα/αα)
Most common cause: gene deletion (unlike β-thal which is point mutations)

Deleted genes	Condition	Clinical Features
1 (αα/α-)	Silent carrier	Asymptomatic
2 (αα/-- or α-/α-)	α-thal trait	Mild microcytic anemia, normal HbA2
3 (α-/--)	HbH disease	Moderate hemolytic anemia, HbH (β₄) = 4 beta chains unstable
4 (--/--)	Hydrops fetalis (Hb Barts)	FATAL in utero; Hb Barts (γ₄) = no oxygen delivery

MCQ: HbH (β₄ tetramers) precipitates in RBCs → Heinz body-like inclusions detected with brilliant cresyl blue stain. Hb Barts disease: baby born with severe hydrops, massive hepatosplenomegaly → incompatible with life.

8.2 β-Thalassemia

β-globin on chromosome 11
Caused by point mutations (>200 known), leading to ↓ (β+) or absent (β⁰) β-chain synthesis
Excess α chains precipitate → destroy RBC precursors in marrow = ineffective erythropoiesis (hallmark)

Condition	Genotype	Features
β-thal minor/trait	β/β+ or β/β⁰	Mild microcytic anemia; HbA₂ elevated (>3.5%) - DIAGNOSTIC; HbF mildly elevated
β-thal intermedia	β+/β+ or β+/β⁰	Moderate anemia; transfusion-independent; splenomegaly
β-thal major (Cooley's anemia)	β⁰/β⁰	Severe transfusion-dependent anemia from 6 months of age

β-thal major clinical features (Pathology + Pediatrics):

Presents at 6 months (when HbF declines)
Chipmunk facies / Frontal bossing (skull X-ray: hair-on-end appearance) due to marrow expansion
Maxillary overgrowth (classic NEET image)
Massive hepatosplenomegaly (EMH)
Growth retardation, endocrinopathies (iron deposition)
Gallstones (chronic hemolysis)
Secondary hemochromatosis from transfusions

Lab:

Severe anemia (Hb may be 3-7 g/dL)
Target cells, nucleated RBCs, tear-drop cells, basophilic stippling
Elevated HbF (major fraction in β⁰/β⁰)
HbA absent (in β⁰/β⁰), HbA₂ elevated

Treatment:

Regular blood transfusions every 3-4 weeks to maintain Hb >9-10 g/dL
Deferasirox (oral, first-line iron chelation), Deferoxamine (IV/SC), Deferiprone (oral, crosses blood-brain barrier)
Splenectomy if transfusion requirement > 200-250 mL/kg/year
BMT = curative (best before development of iron overload)
Gene therapy (Betibeglogene - recently approved by FDA)

MCQ: Diagnosis of β-thal trait: HbA₂ >3.5% on HPLC/Hb electrophoresis. This is how you differentiate β-thal trait from IDA (both microcytic, but HbA₂ is LOW-NORMAL in IDA).

8.3 Thalassemia vs IDA - The Classic Differentiator

Feature	IDA	β-Thal Trait
MCV	↓	↓
Serum ferritin	↓	Normal/↑
Serum iron	↓	Normal
TIBC	↑	Normal
HbA₂	Normal	↑ (>3.5%)
RBC count	↓	Normal or ↑
Mentzer index (MCV/RBC)	>13 = IDA	<13 = Thalassemia

MCQ: Mentzer Index = MCV ÷ RBC count. <13 = thalassemia; >13 = IDA. Simple screening tool when Hb electrophoresis unavailable.

MODULE 9: APLASTIC ANEMIA

Definition: Pancytopenia with hypocellular bone marrow (<25% cellularity) with fatty replacement

Causes:

Idiopathic (most common, autoimmune T-cell destruction of HSCs)
Drugs: Chloramphenicol (most common drug cause, dose-independent, idiosyncratic), NSAIDs, Gold, Carbamazepine, PTU
Viral: Hepatitis (seronegative, ~10%), EBV, CMV, Parvovirus B19
Radiation, Chemicals (Benzene - occupational exposure)
PNH (clonal, related)
Fanconi anemia (inherited, chromosome breaks, short stature, thumb anomalies)

Investigations:

CBC: pancytopenia, absolute reticulocyte count <20,000/μL (severely reduced)
Blood film: normocytic normochromic anemia
Bone marrow trephine biopsy (gold standard): hypocellular, fat replaced, no abnormal cells
Flow cytometry for PNH clone

Severity (Camitta criteria):

Severe AA: BM cellularity <25% + 2 of 3: neutrophils <500/μL, platelets <20,000/μL, reticulocytes <20,000/μL
Very severe AA: same + neutrophils <200/μL

Treatment:

<40 years + HLA-matched sibling: Allogeneic BMT (curative)
>40 years or no matched donor: Immunosuppression = ATG (Anti-thymocyte globulin) + Cyclosporin + Eltrombopag
Supportive: transfusions, G-CSF, infection prophylaxis

MCQ: Chloramphenicol causes two types of bone marrow toxicity: (1) Dose-dependent, reversible suppression (all patients at high doses); (2) Idiosyncratic aplastic anemia (rare, dose-independent, irreversible, fatal).

MODULE 10: POLYCYTHEMIA VERA (PV) - Myeloproliferative Neoplasm

Definition: ↑ RBC mass (primary) due to JAK2 mutation

JAK2 V617F mutation: present in >95% of PV cases (also in 50% ET, 50% MF)

Clinical: Ruddy (plethoric) face, aquagenic pruritus (itching after hot bath - pathognomonic!), splenomegaly, Budd-Chiari syndrome, thrombosis, headache, hypertension

WHO Diagnostic Criteria (2022 revised):

Major:

Hb >16.5 g/dL (men) / >16 g/dL (women) OR Hct >49%/48%
BM biopsy: panmyelosis + pleomorphic mature megakaryocytes
JAK2 V617F or exon 12 mutation

Minor:

Subnormal serum EPO level

Diagnosis: 3 major OR 2 major + 1 minor

Treatment:

Low-risk (<60y, no thrombosis): Phlebotomy + low-dose aspirin
High-risk: Hydroxyurea (cytoreductive)
Ruxolitinib (JAK1/2 inhibitor) for resistant/intolerant cases

MCQ: Aquagenic pruritus occurs due to mast cell and basophil degranulation triggered by water. EPO levels are LOW in PV (primary polycythemia) - this distinguishes it from secondary polycythemia where EPO is high.

MODULE 11: LEUKEMIAS - Overview

11.1 Quick Classification

Type	Key Age	Chromosome	Marker
CML	Adults 30-60	t(9;22) Philadelphia chromosome → BCR-ABL	CD34+, BCR-ABL
AML	Adults	Various; t(15;17) in M3 (APML)	Auer rods, MPO+
ALL	Children (2-10 yr peak)	t(12;21) = best prognosis; t(9;22) = worst	TdT+, CD10+ (CALLA)
CLL	Elderly (>60 yr)	del(13q) most common	CD5+, CD19+, CD23+

MCQ: CML and Philadelphia chromosome = t(9;22) → ABL gene (chr 9) fused to BCR (chr 22) → BCR-ABL fusion protein with constitutive tyrosine kinase activity. Treatment: Imatinib (Gleevec) - first TKI, revolutionized CML treatment.

MCQ: Auer rods (pink needle-like inclusions in myeloblasts) are pathognomonic of AML. Most important in AML-M3 (APML) - presents with DIC. Treatment: ATRA (All-trans retinoic acid) + Arsenic trioxide.

MCQ: CLL = most common adult leukemia in the Western world. Smudge cells (Basket cells) on blood film are pathognomonic. CD5+ B cells (normally a T-cell marker, aberrantly expressed in CLL).

11.2 ALL - Most Tested Childhood Leukemia

Peak age: 2-10 years
Most common childhood malignancy
TdT+ (Terminal deoxynucleotidyl transferase) - marker of immature lymphoid cells
CD10 (CALLA = Common ALL Antigen) - most favorable marker
t(12;21) → ETV6-RUNX1 = best prognosis
t(9;22) (Ph+) = worst prognosis in ALL
CNS involvement common → LP needed at diagnosis

Treatment: Induction (Vincristine + Prednisolone + L-Asparaginase + Anthracycline) → Consolidation → Maintenance (2 years)

MCQ: L-Asparaginase mechanism: leukemic cells lack asparagine synthetase → depend on exogenous asparagine → L-Asp depletes serum asparagine → selective leukemic cell kill. Side effects: pancreatitis, coagulopathy, hepatotoxicity.

MODULE 12: LYMPHOMAS - High Yield

12.1 Hodgkin's Lymphoma (HL)

Reed-Sternberg (RS) cells = hallmark, binucleated owl-eye cells, CD15+, CD30+

Classification (WHO/Modified Ann Arbor):

Type	RS Cells	Prognosis
Nodular sclerosis	Lacunar cells	Most common (70%), young women, mediastinal
Mixed cellularity	Classic RS	2nd most common; EBV associated
Lymphocyte predominant	Popcorn cells (L&H cells); CD20+	Best prognosis
Lymphocyte depleted	Many RS, few lymphocytes	Worst prognosis

Staging (Ann Arbor):

I: Single node group
II: ≥2 node groups, same side of diaphragm
III: Both sides of diaphragm
IV: Extranodal involvement (bone marrow, liver)
B symptoms: Fever >38°C, night sweats, weight loss >10% in 6 months (worse prognosis)

Treatment: ABVD (Adriamycin/Doxorubicin + Bleomycin + Vinblastine + Dacarbazine)

MCQ: HL spreads contiguously (node to node in orderly fashion). NHL spreads non-contiguously. This is why Ann Arbor staging predicts prognosis better in HL than NHL.

12.2 Non-Hodgkin's Lymphoma (NHL) - Key Types

Type	Translocation	Key Feature
Burkitt's lymphoma	t(8;14) → c-MYC	"Starry sky" pattern; EBV associated; jaw mass in Africa; most aggressive
Follicular lymphoma	t(14;18) → BCL-2 overexpression	Most common indolent NHL; CD10+, BCL-2+
Diffuse Large B-Cell (DLBCL)	t(3;14) or various	Most common NHL overall; aggressive but potentially curable
Mantle cell lymphoma	t(11;14) → Cyclin D1	CD5+, CD23-, Cyclin D1+; aggressive, poor prognosis
MALT lymphoma	t(11;18)	H. pylori associated gastric lymphoma; treat H. pylori first

MCQ: Burkitt's lymphoma has the highest proliferation rate of any human tumor (Ki-67 = 100%). c-MYC translocation. Treated with intensive short-duration chemotherapy (not ABVD). EBV association: 100% in endemic (African) form, 30% in sporadic.

MODULE 13: MULTIPLE MYELOMA

Clonal plasma cell disorder producing a monoclonal protein (M-protein)

CRAB criteria:

C = hyperCalcemia
R = Renal failure (Bence Jones protein - free light chains damage tubules)
A = Anemia
B = lytic Bone lesions (punched-out on X-ray)

Also: Recurrent infections (hypogammaglobulinemia), hyperviscosity

Investigations:

SPEP: M-spike (monoclonal band, usually IgG >IgA)
Bence Jones proteinuria (free light chains in urine)
X-ray: Punched-out lytic lesions (skull = "Rain drop skull")
Bone marrow: >10% plasma cells (clonal)
Serum free light chain assay
Rouleaux formation on blood film (RBCs stack like coins - due to high protein)

Diagnosis (IMWG 2014): ≥10% clonal plasma cells in BM + any CRAB criterion OR biomarker (BM >60%, sFLC ratio >100, >1 focal lesion on MRI)

Treatment: Bortezomib (proteasome inhibitor) + Lenalidomide + Dexamethasone (VRD) → autologous SCT in eligible patients

MCQ: Waldenstrom's macroglobulinemia = IgM monoclonal gammopathy (lymphoplasmacytic lymphoma). Presents with hyperviscosity (visual disturbance, headache), NOT lytic bone lesions. Treatment: Ibrutinib, Rituximab.

MODULE 14: COAGULATION - Foundation

14.1 Coagulation Cascade (Simplified NEET Version)

Intrinsic pathway:       XII → XI → IX → VIII → X
                                     ↑
Extrinsic pathway:    Tissue factor + VII → X
                                              ↓
Common pathway:              X + V → Prothrombin (II) → Thrombin → Fibrinogen → Fibrin

Tests:

PT (Prothrombin time) = tests EXTRINSIC + COMMON pathway (Factors VII, X, V, II, fibrinogen)
aPTT/APTT = tests INTRINSIC + COMMON pathway (Factors XII, XI, IX, VIII, X, V, II, fibrinogen)
PT prolonged = liver disease, warfarin, Vitamin K deficiency, Factor VII deficiency
aPTT prolonged = heparin (UFH), hemophilia A (VIII↓), hemophilia B (IX↓), lupus anticoagulant

MCQ - Vitamin K dependent factors: II, VII, IX, X, Protein C, Protein S (mnemonic: "1972" = factors 1,9,7,2 → but K-dependent = 2,7,9,10 + C and S). Warfarin inhibits Vitamin K epoxide reductase → these factors aren't carboxylated → inactive.

14.2 Hemophilia A and B

Feature	Hemophilia A	Hemophilia B (Christmas Disease)
Factor	VIII deficiency	IX deficiency
Inheritance	X-linked recessive	X-linked recessive
aPTT	Prolonged	Prolonged
PT	Normal	Normal
Bleeding time	Normal	Normal
Treatment	Factor VIII concentrate / DDAVP (mild)	Factor IX concentrate

MCQ: DDAVP (Desmopressin) releases stored vWF and Factor VIII from endothelial cells → useful in mild hemophilia A and vWD type 1. NOT useful in hemophilia B or severe hemophilia A.

14.3 Von Willebrand Disease (vWD)

Most common inherited bleeding disorder (autosomal dominant)
vWF: bridges platelet to collagen (primary hemostasis) AND acts as carrier for Factor VIII

Test	Result in vWD
Bleeding time	Prolonged (platelet plug defect)
aPTT	Prolonged (in severe vWD - low Factor VIII)
PT	Normal
Platelet count	Normal
Ristocetin cofactor assay	↓ (diagnostic)

MCQ: Ristocetin agglutination test is key for vWD diagnosis. Ristocetin induces vWF-dependent platelet aggregation. Absent in vWD type 1,2,3. Also absent in Bernard-Soulier syndrome (deficient GP Ib = vWF receptor on platelets). Normal in Glanzmann's thrombasthenia (GPIIb/IIIa defect - can't aggregate).

MODULE 15: THROMBOCYTOPENIA - DIC AND ITP

15.1 ITP (Immune Thrombocytopenic Purpura)

Auto-antibodies (IgG) against GPIIb/IIIa on platelets → splenic macrophage destruction
Acute ITP: Children, post-viral (6-8 weeks), self-limiting
Chronic ITP: Adults (>6 months), H. pylori association

Features: Petechiae, purpura, ecchymoses, mucosal bleeding; NO hepatosplenomegaly (unlike leukemia/hypersplenism)

Investigations: Isolated thrombocytopenia, ↑ megakaryocytes in BM, normal PT/aPTT

Treatment:

Platelet >30,000 + no bleeding: Observe
1st line: Prednisolone, IVIG (for urgent rise), anti-D (in Rh+ patients)
2nd line: Splenectomy, TPO receptor agonists (Eltrombopag, Romiplostim)
Refractory: Rituximab, Fostamatinib

15.2 DIC (Disseminated Intravascular Coagulation)

Simultaneously: widespread clotting + consumption coagulopathy → bleeding
Causes: Sepsis (most common), APML (M3 AML), amniotic fluid embolism, abruption, obstetric catastrophes, snakebite, transfusion reactions, burns

Lab findings:

PT prolonged, aPTT prolonged
Platelet count ↓ (consumed)
Fibrinogen ↓ (consumed)
D-dimer ↑↑ (fibrin degradation products) - most sensitive
Blood film: Schistocytes (microangiopathic hemolysis)

MCQ: APML (AML-M3) has high incidence of DIC - the granules of malignant promyelocytes release tissue factor. Treatment is ATRA + arsenic (ATO) - rapid induction helps prevent DIC death.

MODULE 16: INTEGRATED MCQ BOMBS (Cross-Subject)

16.1 NEET PG One-liners to Memorize

Fact	Subject
Most common anemia in pregnancy = Iron deficiency	Obs-Gynae
Folic acid for NTD prevention: 400 mcg/day periconceptionally	Obs-Gynae
In fetus, hematopoiesis: Liver is the main site at 3rd month	Physiology
Extramedullary hematopoiesis = seen on X-ray as paraspinal mass in thalassemia	Radiology
Ferritin = acute phase reactant (↑ in inflammation; may mask IDA)	Biochemistry
Folate body stores last 3-4 months (B12 lasts 3-5 years)	Biochemistry
Heinz bodies = denatured Hb precipitate (G6PD, unstable Hb) - seen on supravital stain	Pathology
Howell-Jolly bodies = nuclear remnants in RBCs = asplenia/post-splenectomy	Pathology
Cabot rings = remnants of mitotic spindle in RBCs = megaloblastic anemia	Pathology
Basophilic stippling = aggregated ribosomes = lead poisoning, thalassemia, sideroblastic anemia	Pathology
Pencil/cigar cells = IDA	Pathology
Schistocytes = TTP, HUS, DIC, mechanical heart valves, MAHA	Pathology
Tear-drop cells (Dacrocytes) = Myelofibrosis (leukoerythroblastic picture)	Pathology
Target cells = HALT: HbC disease, Asplenia/post-splenectomy, Liver disease, Thalassemia	Pathology
Leukoerythroblastic blood film = nucleated RBCs + immature WBCs → bone marrow infiltration	Pathology
ESR raised in pregnancy (physiological) due to ↑ fibrinogen	Physiology
Wiskott-Aldrich syndrome = X-linked; eczema + thrombocytopenia + infections	Pediatrics
Fanconi anemia = autosomal recessive; aplastic anemia + radial ray defects + short stature; ↑ chromosomal breaks with MMC/DEB test	Pediatrics
Paroxysmal Cold Hemoglobinuria = Donath-Landsteiner Ab (IgG, biphasic)	Medicine
PNH = CD55, CD59 deficiency → complement-mediated intravascular hemolysis; thrombosis; Budd-Chiari	Medicine
Coombs positive hemolysis = AIHA (warm = IgG, cold = IgM)	Medicine
Ham's test (acidified serum lysis) = PNH (replaced by flow cytometry for CD55/CD59)	Medicine
Philadelphia chromosome = CML (>95%), ALL (25%), occasionally AML	Pathology

16.2 Classic NEET PG Blood Film Images

Blood Film Finding	Diagnosis
Hypersegmented neutrophils	Megaloblastic anemia (earliest sign)
Smudge/basket cells	CLL
Auer rods in blasts	AML
Owl-eye Reed-Sternberg cells	Hodgkin's lymphoma
Rouleaux formation	Multiple myeloma
Spherocytes + direct Coombs +	AIHA
Spherocytes + direct Coombs -	Hereditary spherocytosis
Target cells + ↑ HbA₂	β-thalassemia
Pencil cells + ↑ TIBC + ↓ ferritin	IDA
Schistocytes + low platelets	TTP/HUS/DIC
Tear-drop cells + nucleated RBCs	Myelofibrosis

MODULE 17: SUBJECT INTEGRATION SUMMARY

This is how the 19 NEET PG subjects appear in Hematology:

Subject	Key Hematology Connection
Physiology	Normal values, ODC, erythropoiesis regulation, EPO
Biochemistry	Iron metabolism, Hb structure, B12/folate pathways, hepcidin
Pathology	Blood film, BM biopsy, leukemias, lymphomas, coagulation disorders
Medicine (Internal)	Anemia diagnosis/treatment, CML, CLL, MM, bleeding disorders
Pediatrics	SCD, thalassemia, ALL, HS, neonatal jaundice, aplastic anemia
Obstetrics	Anemia in pregnancy, folate for NTD, HELLP syndrome (thrombocytopenia)
Surgery	Coagulation before surgery, DIC, blood transfusion, splenectomy
Pharmacology	Hydroxyurea, Imatinib, ATRA, chelation therapy, hematinics, anticoagulants
Microbiology	Malaria (RBC destruction), EBV (lymphoma), Parvovirus B19 (aplastic crisis), Plasmodium falciparum (MAHA)
Forensic Medicine	CO poisoning (cherry red HbCO), lead poisoning (basophilic stippling, sideroblastic anemia)
SPM/Community	Prevalence of IDA, national programs (WIFS - weekly iron-folic acid), G6PD screening neonates
Radiology	Hair-on-end skull (thalassemia), punched-out lesions (myeloma), paraspinal mass (EMH)
Ophthalmology	Proliferative retinopathy (SCD), hyperviscosity fundus (Waldenstrom's, PV)
Genetics	Chromosomal translocations in leukemia, prenatal diagnosis, G-banding
Immunology	Lymphocyte development, lymphoma immunophenotyping, AIHA mechanisms
Orthopedics	AVN femoral head (SCD), bone infarcts, Salmonella osteomyelitis
Nephrology	Anemia of CKD (↓ EPO), TTP-HUS (thrombotic microangiopathy), myeloma kidney
Endocrinology	Pernicious anemia (thyroid autoimmunity association), iron overload endocrinopathy in thal
Dermatology	Koilonychia (IDA), petechiae/purpura (platelet disorders), jaundice (hemolysis)

QUICK REVISION TABLE - MOST TESTED MCQ NUMBERS

What	Number
Hb threshold for anemia: Men	<13 g/dL
Hb threshold for anemia: Women	<12 g/dL
Hb in pregnancy (WHO anemia)	<11 g/dL
Normal MCV	80-100 fL
Normal MCHC	32-36 g/dL
Normal platelets	1.5-4 lakh/mm³
Serum ferritin (IDA = low)	Normal: 12-300 ng/mL (men); 12-150 (women)
Transferrin saturation (IDA)	<15% (normal: ~33%)
Normal TIBC	300-350 μg/dL
HbA₂ in β-thal trait	>3.5%
Mentzer index: IDA	>13
Mentzer index: Thalassemia	<13
Reticulocyte rise after iron therapy	7-10 days
Hb rise after iron therapy	1-2 g/dL per month
Body iron: women/men	2.5 g / 3.5 g
B12 body stores duration	3-5 years
Folate body stores duration	3-4 months
Age for peak ALL	2-10 years
Philadelphia chromosome in CML	>95%

This session covers Module 1-17. Each module integrates the relevant subjects from across NEET PG.

What to do next:

Tell me which module to go DEEPER into (e.g., "explain TTP vs HUS vs DIC in detail")
Ask for a specific MCQ practice set from any module
Ask for the next topic batch: Transfusion medicine, Bone marrow transplant, Myeloproliferative neoplasms, Myelodysplastic syndrome

This is a shared conversation. Sign in to Orris to start your own chat.